Lonza, a contract development and manufacturing organization (CDMO), has strengthened its Advanced Synthesis offering to increase phase-appropriate support for the discovery and development of antibody-drug conjugates (ADCs) and other bioconjugates. The strengthened offering includes the full integration of the ADC technology platform, which will now be offered by Lonza as part of its Advanced Synthesis portfolio. The platform comprises the proprietary GlycoConnect antibody conjugation techno...